# A Study of BGM0504 Injection in Participants with Obesity or Overweight

> **NCT06704581** · PHASE3 · RECRUITING · sponsor: **BrightGene New Bio-Medical Technology(Wuxi) Co.Ltd.** · enrollment: 620 (estimated)

## Conditions studied

- Overweight or Obesity

## Interventions

- **DRUG:** 5 mg BGM0504 injection
- **DRUG:** 10 mg BGM0504 injection administered subcutaneously (SC) once a week
- **DRUG:** 15 mg BGM0504 injection
- **DRUG:** BGM0504 placebo

## Key facts

- **NCT ID:** NCT06704581
- **Lead sponsor:** BrightGene New Bio-Medical Technology(Wuxi) Co.Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-28
- **Primary completion:** 2025-11-27
- **Final completion:** 2026-03-27
- **Target enrollment:** 620 (ESTIMATED)
- **Last updated:** 2024-11-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06704581

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06704581, "A Study of BGM0504 Injection in Participants with Obesity or Overweight". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06704581. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*